New Hampshire to Receive $30 Million From Purdue-Sackler Opioid Settlement

New Hampshire will receive more than $29.5 million from Purdue Pharma and the Sackler family as the nationwide $7.4 billion opioid settlement becomes legally effective this month. The funds, announced by Attorney General John Formella, will flow into prevention, treatment, and recovery programs across the Granite State over the coming years.

State officials anticipate that approximately $16.2 million—slightly more than half the total allocation—will be disbursed during the first three years. The settlement represents the culmination of a decade-long investigation and litigation effort joined by attorneys general from every state and eligible U.S. territory, finally resolving claims against the manufacturer of OxyContin.

Accountability and Permanent Industry Ban

As a provision of the settlement, the Sackler family, which owned and controlled Purdue Pharma, is permanently banned from selling opioids in the United States. The family has been widely regarded as fueling the opioid crisis through aggressive marketing of prescription painkillers that downplayed addiction risks and flooded communities with highly addictive medications.

"For too long, they profited while communities like ours paid the price," Formella said in a statement. "While no amount of money can undo the harm caused to families across New Hampshire, this agreement delivers both accountability and meaningful resources."

The settlement follows years of legal battles, including Purdue's 2019 bankruptcy filing and the Supreme Court's 2024 invalidation of an earlier agreement that would have shielded the Sacklers from personal liability. The current deal requires the family to contribute $1.5 billion immediately, with additional payments structured over 15 years.

Distribution Framework and Local Allocation

New Hampshire's settlement funds will be distributed through a two-track system established under state law. Fifteen percent of the total—approximately $4.5 million—will be divided among all cities and counties based on population. This direct allocation ensures that local governments receive resources proportional to their community size and need.

The remaining 85 percent will flow into the state's Opioid Abatement Trust Fund, where an advisory commission determines which specific organizations and programs receive funding. This structure allows for strategic, evidence-based deployment of resources while maintaining local flexibility.

The commission has already begun awarding grants to community organizations, treatment providers, and prevention initiatives. Previous rounds of opioid settlement funding have supported medication-assisted treatment expansion, recovery housing, peer support services, and school-based prevention education.

Crisis Context in the Granite State

The opioid crisis peaked in New Hampshire in 2017, when the state recorded 416 opioid-related deaths—roughly 33.4 per 100,000 residents. The mortality rate, among the highest in the nation at that time, devastated families and strained emergency services, healthcare systems, and law enforcement agencies across the state.

While deaths declined somewhat in subsequent years, the pandemic brought a resurgence as isolation, economic disruption, and disrupted treatment access combined to drive overdose fatalities upward. In 2024, the state recorded 248 overdoses involving opioids, a figure that remains elevated compared to pre-crisis baselines but reflects some progress from the worst years.

Fentanyl, the synthetic opioid that has largely displaced prescription painkillers in the illicit drug supply, now drives the majority of overdose deaths in New Hampshire. The shift from pharmaceutical opioids to illicit fentanyl has complicated response efforts, as harm reduction strategies must adapt to substances of unpredictable potency and composition.

Strategic Priorities for Settlement Deployment

The Opioid Abatement Trust Fund advisory commission has outlined several priority areas for settlement investment. Treatment expansion remains the top priority, with particular emphasis on medication-assisted treatment using buprenorphine and methadone—the evidence-based standard for opioid use disorder care.

Prevention programs targeting youth have received significant attention, including school-based education initiatives and community outreach designed to prevent initial opioid use. The commission has also funded recovery support services, including peer recovery coaches who use their own lived experience to guide others through the challenges of maintaining long-term recovery.

Harm reduction strategies, including naloxone distribution and syringe service programs, continue to receive support despite shifting federal policy. The state's approach reflects a comprehensive public health framework that addresses the crisis through multiple intervention points.

Challenges and Opportunities

The settlement arrives as New Hampshire, like other states, grapples with workforce shortages in addiction medicine and behavioral health. Even with adequate funding, expanding treatment capacity requires trained clinicians, counselors, and peer support specialists—a challenge exacerbated by national shortages and competitive labor markets.

Rural areas of the state face particular barriers, with geographic isolation limiting access to specialty care and medication-assisted treatment providers. Telehealth expansion, accelerated during the pandemic, has helped bridge some gaps, but broadband access limitations and regulatory complexities continue to constrain remote care delivery.

The 15-year payment structure of the settlement provides long-term revenue for addiction services, but also requires sustainable planning. State officials emphasize the importance of building infrastructure and programs that can persist beyond the settlement period, rather than creating time-limited initiatives that will expire when funds run out.

National Context and Ongoing Litigation

New Hampshire's $29.5 million allocation represents a portion of the $7.4 billion national settlement with Purdue Pharma and the Sackler family. The deal, which took effect May 1, 2026, permanently dissolves Purdue as a corporate entity and transfers its manufacturing operations to Knoa Pharma under independent oversight.

The settlement also requires public release of more than 30 million internal company documents, potentially shedding light on the marketing strategies and decision-making that fueled the opioid crisis. Researchers, journalists, and policymakers anticipate that these documents will provide unprecedented insight into pharmaceutical industry practices.

Separate from the Purdue settlement, New Hampshire and other states continue litigation against other manufacturers, distributors, and pharmacy chains. The state has already secured additional millions from settlements with companies including Johnson & Johnson, McKesson, Cardinal Health, and CVS, with total opioid-related recoveries expected to exceed $100 million over the coming years.

Attorney General Formella emphasized the ongoing nature of accountability efforts. "We remain committed to working with our local partners to ensure these funds are used where they are needed most to save lives and support long-term recovery," he said. "This settlement is a significant step, but our work continues."